ERCC1、ERCC2在食管癌细胞株中的表达及与顺铂、紫杉醇敏感性相关研究
|
摘要
目的:ERCC1(excision repair cross complementing1)和ERCC2(excision repair cross complementing2)即核苷酸切除修复交叉互补基因1和2,两者分别在DNA损伤修复中发挥受损DNA 5’端外切和双链解螺旋作用。大量文献和临床资料已经证实两者表达水平上调是铂类化疗药物耐药的重要分子基础。同时有资料显示ERCC2蛋白水平与抗有丝分裂剂紫杉醇敏感性呈显著负相关。尚无其mRNA水平与紫杉醇敏感性相关报道。顺铂和紫杉醇为经典化疗药物,在食管癌化疗中起着举足轻重的作用,但化疗并非对所有患者都有效。如何筛选出化疗敏感个体,减少陪疗人群,实现个体化化疗是目前研究热点。本研究通过测定6株常见食管鳞癌细胞株中ERCC1和ERCC2 mRNA水平表达,比较其表达水平与顺铂、紫杉醇药物敏感性的关系。并进一步研究了siRNA下调ERCC2表达后顺铂和紫杉醇敏感性的变化。以求在食管癌细胞株中证实ERCC1和ERCC2 mRNA水平与顺铂敏感性的关系,及探讨ERCC2 mRNA表达与紫杉醇敏感性的相关性。为临床筛选敏感个体和敏感药物,实现个体化化疗提供资料。
方法:
第一部分
1培养国内常用食管鳞癌细胞株6株。RT-PCR法测定各细胞株ERCC1、ERCC2 mRNA表达及其表达相关性。
2 MTT法测定浓度梯度的顺铂、紫杉醇作用24h后的IC50值(抑制率50%时的药物浓度)。比较两因子mRNA水平与顺铂、紫杉醇IC50值的相关性。
第二部分
1应用体外合成靶向ERCC2的siRNA(si-ERCC2),脂质体法瞬时转染ERCC2高表达细胞株KYSE150。同时设阴性对照、脂质体对照和空白对照组。RT-PCR和流式细胞术(FCM)分别检测各转染组细胞ERCC2 mRNA和蛋白水平的表达。
2 MTT法检测各转染组细胞浓度梯度顺铂和紫杉醇的抑制率,计算IC50值。比较转染前后顺铂和紫杉醇IC50值的变化。
结果:
第一部分
1 ERCC1和ERCC2 mRNA表达情况
ERCC1表达:6株细胞均可测出ERCC1特异性条带,相对表达量在0.8214~0.1709间不等。表达最高的Eca109和最低的TE10表达量相差4.81倍。
ERCC2表达:TE13未测出ERCC2条带,为不表达ERCC2细胞株。余5株细胞可测出ERCC2表达。以KYSE150表达量最高,为0.8712。余4株细胞表达量在0.0870~0.2033间不等。与表达最高的KYSE150表达量相差4~10倍。
ERCC1和ERCC2表达相关系数Rs=0.258,P=0.076 >0.05。两因子表达存在相关趋势,但无统计学意义。
2浓度梯度顺铂和紫杉醇作用24h后各细胞株IC50值及与ERCC1和ERCC2 mRNA表达的相关性
顺铂IC50值在15.17±2.11ug/ml到42.84±3.82ug/ml间不等。其中KYSE150最高,TE13最低。两者相差2.82倍。
紫杉醇IC50值在3.44±1.05ug/ml到12.85±2.17ug/ml间不等。其中KYSE150最高,TE1最低。两者相差3.74倍。
ERCC1 mRNA水平与顺铂IC50值相关系数Rs=0.835,P<0.01。呈明显正相关。ERCC1 mRNA表达水平越高,顺铂IC50值越高,顺铂敏感性越低。
ERCC2 mRNA水平与顺铂IC50值相关系数Rs=0.379,P<0.01。呈明显正相关。ERCC2 mRNA表达水平越高,顺铂IC50值越高,顺铂敏感性越低。
ERCC1 mRNA水平与紫杉醇IC50值相关系数Rs= 0.180,P>0.05。两者之间无明显相关性。
ERCC2 mRNA水平与紫杉醇IC50值相关系数Rs= 0.293,P<0.05。呈明显正相关。ERCC2 mRNA表达水平越高,紫杉醇IC50值越高,紫杉醇敏感性越低。
第二部分
1 siRNA转染KYSE150后ERCC2 mRNA及蛋白水平表达
转染后ERCC2 mRNA水平表达:si-ERCC2组在转染后24、48、72h于相应部位均未测出ERCC2特异性条带。而三组对照三个时段均可见特异性条带,表达量间无明显差别(P>0.05)。说明si-ERCC2成功封闭了目的基因mRNA水平的表达。而三组对照对目的基因无干扰作用。
转染后ERCC2蛋白水平表达:si-ERCC2组转染24、48、72h后ERCC2蛋白表达量分别为0.688±0.11,0.484±0.09和0.400±0.04。较对照组分别下调31.2%,51.6%和60.0%。而三组对照表达量无明显差别(P>0.05)。表明si-ERCC2成功下调了目的基因蛋白水平的表达,而三组对照对其无下调作用。
2 siRNA转染KYSE150后顺铂和紫杉醇IC50值的变化
si-ERCC2组顺铂IC50值为26.41±2.63ug/ml,较对照组40.32±3.44ug/ml降低34%。紫杉醇IC50值为6.32±0.87ug/ml,较对照组的12.66±1.69ug/ml降低49%。明显低于三组对照(P<0.01)。说明下调ERCC2表达降低了顺铂和紫杉醇IC50值,增加了两药敏感性。
结论:
1所测食管癌细胞株ERCC1、ERCC2有不同程度表达。
2 ERCC1和ERCC2 mRNA水平均与顺铂敏感性呈负相关,ERCC2 mRNA水平与紫杉醇敏感性呈负相关。ERCC1 mRNA水平与紫杉醇敏感性无关。
3转染siRNA成功下调了ERCC2 mRNA和蛋白水平的表达。
4转染后细胞部分恢复了对顺铂和紫杉醇的敏感性,逆转了两药耐药,进一步说明ERCC2同时参与顺铂和紫杉醇耐药。
Objective: ERCC1 (excision repair cross complementing 1) and ERCC2 (excision repair cross complementing 2) are leading members in DNA repair pathway. ERCC1 can execute the 5’incision and ERCC2 can open the damaged DNA double strand. Preclinical studies and clinical trials have confirmed that both genes were related to cisplatin (DDP) resistance. And a few data suggested that ERCC2 protein level might affect paclitaxel (PTX) sensitivity. There is no report about the relationship between ERCC2 mRNA and PTX up to now. DDP and PTX are effective agents and commonly used in esophageal carcinoma. But chemotherapy is not efftctive in all patients. How to select the chemosensitive individual and sensitivity drug is of great importance. This article detect the ERCC1 and ERCC2mRNA expression in 6 common esophageal carcinoma cell lines, and the IC50 after DDP and PTX treated for 24h. We evaluat the relationship between gene expression and DDP/PTX sensitivity. Moreover, we transfect KYSE150 using ERCC2 siRNA(small interfering RNA) cell, which harbored the highest ERCC2 mRNA. To observe the impact of ERCC2 siRNA transfecting on drug sensitivity.
Methods:
Section 1
1 ERCC1 and ERCC2 mRNA of six esophageal carcinoma cell lines are detected by Reverse transcription polymerase (RT-PCR) .To observe the gene expression correlation.
2 MTT are used to detect IC50 after DDP and PTX treated for 24h. To observe the correlation between IC50 and gene expression.
Section 2
1 Lipofectmine2000 are used to transfect siRNA into the cell KYSE150. The negative-control, lipofectmine 2000 and bl- ank control group are established.
2 ERCC2 mRNA and protein expression are assayed by RT-PCR and FCM after transfection 24h,48h,72h respectively.
3 IC50 of DDP and PTX are detected by MTT after transfection.
Results:
Section 1
1 ERCC1 mRNA is detected in all the 6 cell lines. The high-est expression cell line is Eca109 (0.8214), and the lowest is TE10 (0.1709). The highest is 4.81 times higher than the lowest.
ERCC2 mRNA is detected in 5 cell lines except TE13. The highest expression cell line is KYSE150(0.8712), and the lowest is KYSE450 (0.0870). The highest is 4~10 times higher than the lowest. TE13 is under detectable line.
There is no significant correlation between the expression of ERCC1 and ERCC2 (P=0.076).
2 DDP IC50(ug/ml) is from 15.17±2.11 to 42.84±3.82 in 6 cells, while KYSE150 is the highest and TE13 is the lowest. The highest is 2.82 times than the lowest.
PTX IC50(ug/ml) is from 3.44±1.05 to 12.85±2.17 in 6 cells, while KYSE150 is the highest and TE1 is the lowest. The highest is 3.74 times than the lowest.
There is a positive correlation between ERCC1, ERCC2 mRNA and DDP IC50(P<0.01).
A positive correlation between ERCC2 mRNA and DDP IC50(P<0.01) is found. And the correlation between ERCC1 mRNA and PTX IC50 is no statistical significance (P>0.05).
Section 2
1 ERCC2 mRNA is not detectable in KYSE150 by RT- PCR after transfection for 24h, 48h and 72h in si-ERCC2 group. As for 3 control groups, ERCC2 level was no significant differ -ence compared with baseline (P>0.05).
ERCC2 protein expression are 0.688±0.11, 0.484±0.09 and 0.400±0.04 after transfection for 24h,48h,72h. Compared with baseline, ERCC2 proein are descent 31.2%,51.6%,60.0% resp- ectively. Control groups are no any significance campared with the baseline(P>0.05). It indicates that siRNA could down- regulate ERCC2 in mRNA and protein level.
2 IC50 (ug/ml) for DDP is 26.41±2.63 after transfection, which decrease 34%. PTX IC50 is 6.32±0.87 after transfection, is 49% decreased.si-ERCC2 IC50 is much lower than control groups (P<0.01). There is no any significance among control groups (P>0.05). The result suggests that DDP and PTX sensi- tivity increased after transfection.
Conclusions:
1 ERCC1 and ERCC2 is express in esophageal carcinoma cell lines at different levels. ERCC1 and ERCC2 expression are relate to DDP sensitivity, and ERCC2 mRNA are also correlate with PTX sensitivity.
2 ERCC2 siRNA can dramaticlly down-regulate the expre- ssion of ERCC2 mRNA and protein.
3 After transfection of ERCC2 siRNA, the cell partially revers DDP and PTX resistance. Futher support the presume that ERCC2 is not only involved in cisplatin resistance,but also make a contribution to Paclixetal resistance.
方法:
第一部分
1培养国内常用食管鳞癌细胞株6株。RT-PCR法测定各细胞株ERCC1、ERCC2 mRNA表达及其表达相关性。
2 MTT法测定浓度梯度的顺铂、紫杉醇作用24h后的IC50值(抑制率50%时的药物浓度)。比较两因子mRNA水平与顺铂、紫杉醇IC50值的相关性。
第二部分
1应用体外合成靶向ERCC2的siRNA(si-ERCC2),脂质体法瞬时转染ERCC2高表达细胞株KYSE150。同时设阴性对照、脂质体对照和空白对照组。RT-PCR和流式细胞术(FCM)分别检测各转染组细胞ERCC2 mRNA和蛋白水平的表达。
2 MTT法检测各转染组细胞浓度梯度顺铂和紫杉醇的抑制率,计算IC50值。比较转染前后顺铂和紫杉醇IC50值的变化。
结果:
第一部分
1 ERCC1和ERCC2 mRNA表达情况
ERCC1表达:6株细胞均可测出ERCC1特异性条带,相对表达量在0.8214~0.1709间不等。表达最高的Eca109和最低的TE10表达量相差4.81倍。
ERCC2表达:TE13未测出ERCC2条带,为不表达ERCC2细胞株。余5株细胞可测出ERCC2表达。以KYSE150表达量最高,为0.8712。余4株细胞表达量在0.0870~0.2033间不等。与表达最高的KYSE150表达量相差4~10倍。
ERCC1和ERCC2表达相关系数Rs=0.258,P=0.076 >0.05。两因子表达存在相关趋势,但无统计学意义。
2浓度梯度顺铂和紫杉醇作用24h后各细胞株IC50值及与ERCC1和ERCC2 mRNA表达的相关性
顺铂IC50值在15.17±2.11ug/ml到42.84±3.82ug/ml间不等。其中KYSE150最高,TE13最低。两者相差2.82倍。
紫杉醇IC50值在3.44±1.05ug/ml到12.85±2.17ug/ml间不等。其中KYSE150最高,TE1最低。两者相差3.74倍。
ERCC1 mRNA水平与顺铂IC50值相关系数Rs=0.835,P<0.01。呈明显正相关。ERCC1 mRNA表达水平越高,顺铂IC50值越高,顺铂敏感性越低。
ERCC2 mRNA水平与顺铂IC50值相关系数Rs=0.379,P<0.01。呈明显正相关。ERCC2 mRNA表达水平越高,顺铂IC50值越高,顺铂敏感性越低。
ERCC1 mRNA水平与紫杉醇IC50值相关系数Rs= 0.180,P>0.05。两者之间无明显相关性。
ERCC2 mRNA水平与紫杉醇IC50值相关系数Rs= 0.293,P<0.05。呈明显正相关。ERCC2 mRNA表达水平越高,紫杉醇IC50值越高,紫杉醇敏感性越低。
第二部分
1 siRNA转染KYSE150后ERCC2 mRNA及蛋白水平表达
转染后ERCC2 mRNA水平表达:si-ERCC2组在转染后24、48、72h于相应部位均未测出ERCC2特异性条带。而三组对照三个时段均可见特异性条带,表达量间无明显差别(P>0.05)。说明si-ERCC2成功封闭了目的基因mRNA水平的表达。而三组对照对目的基因无干扰作用。
转染后ERCC2蛋白水平表达:si-ERCC2组转染24、48、72h后ERCC2蛋白表达量分别为0.688±0.11,0.484±0.09和0.400±0.04。较对照组分别下调31.2%,51.6%和60.0%。而三组对照表达量无明显差别(P>0.05)。表明si-ERCC2成功下调了目的基因蛋白水平的表达,而三组对照对其无下调作用。
2 siRNA转染KYSE150后顺铂和紫杉醇IC50值的变化
si-ERCC2组顺铂IC50值为26.41±2.63ug/ml,较对照组40.32±3.44ug/ml降低34%。紫杉醇IC50值为6.32±0.87ug/ml,较对照组的12.66±1.69ug/ml降低49%。明显低于三组对照(P<0.01)。说明下调ERCC2表达降低了顺铂和紫杉醇IC50值,增加了两药敏感性。
结论:
1所测食管癌细胞株ERCC1、ERCC2有不同程度表达。
2 ERCC1和ERCC2 mRNA水平均与顺铂敏感性呈负相关,ERCC2 mRNA水平与紫杉醇敏感性呈负相关。ERCC1 mRNA水平与紫杉醇敏感性无关。
3转染siRNA成功下调了ERCC2 mRNA和蛋白水平的表达。
4转染后细胞部分恢复了对顺铂和紫杉醇的敏感性,逆转了两药耐药,进一步说明ERCC2同时参与顺铂和紫杉醇耐药。
Objective: ERCC1 (excision repair cross complementing 1) and ERCC2 (excision repair cross complementing 2) are leading members in DNA repair pathway. ERCC1 can execute the 5’incision and ERCC2 can open the damaged DNA double strand. Preclinical studies and clinical trials have confirmed that both genes were related to cisplatin (DDP) resistance. And a few data suggested that ERCC2 protein level might affect paclitaxel (PTX) sensitivity. There is no report about the relationship between ERCC2 mRNA and PTX up to now. DDP and PTX are effective agents and commonly used in esophageal carcinoma. But chemotherapy is not efftctive in all patients. How to select the chemosensitive individual and sensitivity drug is of great importance. This article detect the ERCC1 and ERCC2mRNA expression in 6 common esophageal carcinoma cell lines, and the IC50 after DDP and PTX treated for 24h. We evaluat the relationship between gene expression and DDP/PTX sensitivity. Moreover, we transfect KYSE150 using ERCC2 siRNA(small interfering RNA) cell, which harbored the highest ERCC2 mRNA. To observe the impact of ERCC2 siRNA transfecting on drug sensitivity.
Methods:
Section 1
1 ERCC1 and ERCC2 mRNA of six esophageal carcinoma cell lines are detected by Reverse transcription polymerase (RT-PCR) .To observe the gene expression correlation.
2 MTT are used to detect IC50 after DDP and PTX treated for 24h. To observe the correlation between IC50 and gene expression.
Section 2
1 Lipofectmine2000 are used to transfect siRNA into the cell KYSE150. The negative-control, lipofectmine 2000 and bl- ank control group are established.
2 ERCC2 mRNA and protein expression are assayed by RT-PCR and FCM after transfection 24h,48h,72h respectively.
3 IC50 of DDP and PTX are detected by MTT after transfection.
Results:
Section 1
1 ERCC1 mRNA is detected in all the 6 cell lines. The high-est expression cell line is Eca109 (0.8214), and the lowest is TE10 (0.1709). The highest is 4.81 times higher than the lowest.
ERCC2 mRNA is detected in 5 cell lines except TE13. The highest expression cell line is KYSE150(0.8712), and the lowest is KYSE450 (0.0870). The highest is 4~10 times higher than the lowest. TE13 is under detectable line.
There is no significant correlation between the expression of ERCC1 and ERCC2 (P=0.076).
2 DDP IC50(ug/ml) is from 15.17±2.11 to 42.84±3.82 in 6 cells, while KYSE150 is the highest and TE13 is the lowest. The highest is 2.82 times than the lowest.
PTX IC50(ug/ml) is from 3.44±1.05 to 12.85±2.17 in 6 cells, while KYSE150 is the highest and TE1 is the lowest. The highest is 3.74 times than the lowest.
There is a positive correlation between ERCC1, ERCC2 mRNA and DDP IC50(P<0.01).
A positive correlation between ERCC2 mRNA and DDP IC50(P<0.01) is found. And the correlation between ERCC1 mRNA and PTX IC50 is no statistical significance (P>0.05).
Section 2
1 ERCC2 mRNA is not detectable in KYSE150 by RT- PCR after transfection for 24h, 48h and 72h in si-ERCC2 group. As for 3 control groups, ERCC2 level was no significant differ -ence compared with baseline (P>0.05).
ERCC2 protein expression are 0.688±0.11, 0.484±0.09 and 0.400±0.04 after transfection for 24h,48h,72h. Compared with baseline, ERCC2 proein are descent 31.2%,51.6%,60.0% resp- ectively. Control groups are no any significance campared with the baseline(P>0.05). It indicates that siRNA could down- regulate ERCC2 in mRNA and protein level.
2 IC50 (ug/ml) for DDP is 26.41±2.63 after transfection, which decrease 34%. PTX IC50 is 6.32±0.87 after transfection, is 49% decreased.si-ERCC2 IC50 is much lower than control groups (P<0.01). There is no any significance among control groups (P>0.05). The result suggests that DDP and PTX sensi- tivity increased after transfection.
Conclusions:
1 ERCC1 and ERCC2 is express in esophageal carcinoma cell lines at different levels. ERCC1 and ERCC2 expression are relate to DDP sensitivity, and ERCC2 mRNA are also correlate with PTX sensitivity.
2 ERCC2 siRNA can dramaticlly down-regulate the expre- ssion of ERCC2 mRNA and protein.
3 After transfection of ERCC2 siRNA, the cell partially revers DDP and PTX resistance. Futher support the presume that ERCC2 is not only involved in cisplatin resistance,but also make a contribution to Paclixetal resistance.
引文
1 Rosell R,Taron M, Camps C. Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today, 2003,39(10):775~786
2 Pierre-Henri L,Gailld and RichardD. Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair. Nucleic Acids Research, 2001, 29(4): 872~879
3 Dabholkar MD, Berger MS, Vionnet JA, et al. Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. CancerRes, 1995, 55:1261~1266
4 Laat W. L, Jaspers G, HoeijmaJ, et al.Molecular mechanicsm of nucleotide excision repair.Genes Dev,1999,13:768~785
5 Chen,JS. Larochelle, X. Li, et al. Xpd/Ercc2 regulates CAK activity and mitotic progression.Nature,2003,4(24):228~232
6 Egly, J. M. TFIIH: from transcription to clinic. FEBS Lett, 2001,498:124~128
7 Fisher, R. P. Secrets of a double agent: CDK7 in cell cycle control and transcription. Cell Sci, 2005,118:5171~5180
8 Morgan, D. O, et al.Principles of CDK regulation. Nature, 1995,374:131~134
9 陈忠平,Anne MONKS,Timoth G,et al.人肿瘤细胞 ERCC2基因表达与抗癌药耐药的相关性.中山医科大学学报, 2001,22(3):170~173
10 Dabholkar M,Bostick-Bruton F,Weber C,et al.Expression ofexcision repair genes in non-malignant bone marrow from cancer patients.Res,1993,293(2):151~160
11 G Weeda, I. Donker, J de Wit, et al. Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence.Cur Biol,1997, 7:427~439
12 黄培钰 , 梁晓曼 , 张力等 . 晚期非小细胞肺癌组织中ERCC1、Metallothionein、p53 表达与铂类耐药性及预后的相关性分析.癌症,2004,23(7):845~850
13 Gerard Mohr, Lawrence C Panasci, 陈忠平等. PCR 定量分析 ERCC2 基因在人类肿瘤细胞中的表达.江苏医药,1998,24(11):781~784
14 汤春辉,顾星星.卵巢癌实体瘤 ERCC2 表达与肿瘤发生及耐药的关系.肿瘤研究与临床,2004,16(1):14~16
15 周宜开,吕斌,张霞等.DNA 切除修复标志物在肺癌、食管癌组织中的表达.环境与职业医学,2003,20(3):145~147
16 Rafael Rosell, Enriqueta Felip, Miquel Taron, et al. Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery. Clinical Cancer Research,2004,10:4215~4219
17 SelvakumaranM, Pisarcik DA, Bao R, et al.Enhanced cis- platin cytotoxicity by disturbing the nucleotide excision repair path way in ovarian cancer cell lines CancerRes,2003, 63:1311~1316
18 Lee KB, Parker RJ, Reed E. Cisplatin sensitivity/resistance in UV repair deficient Chinese hamster ovary cells of complement ation groups 1 and 3.Carcinogenesis, 1993,14: 77~80
19 Yu JJ, Mu C, Reed E, et al.Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. Int J Mol Med,1998,1:17~20
20 Yu JJ, Thornton K, Reed E, et al. An ERCC1 splicing variant involving the 5'UTR of the mRNA may have a transcription- al modulatory function. Oncogene, 2001, 20:7694
21 Dabholkar M, Vionnet J,Bostick-Bruton FE, et al. Expression of an alternatively spliced ERCC1 mRNA species is relatedto reduced DNA repair efficiency in human T lymphocytes. Oncology Rep,1995,2:9~14.
22 Eddie Reed. ERCC1 and Clinical Resistance to Platinum Based Therapy. Clinical Cancer Research, 2005,11:6100~ 6102
23 R. Rosell, M. Cobo, D. Isla, et al.Pharmacogenomics and gemcitabine. Annals of Oncology,2006,17:13~16
24 Eddie Reed.ERCC1 and Clinical Resistance to Platinum Based Therapy.Clinical Cancer Research,2005,11:6100~ 6102
25 P Ceppi, M Volante, S Novello, et al. ERCC1 and RRM1 gene e expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Annals of Oncology, 2006, 17(12): 1818~1825
26 K. Lee, S. Han, H. Min, et al. ERCC1 expression by immuno histochemistry and EGFR mutations in resected non-small cell lung cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings,2007:7646
27 Jean-Charles Soria.ERCC1-Tailored Chemotherapy in Lung Cancer: The First Prospective Randomized Trial.Journal of Clinical Oncology,2007,25, (19 ):2648~2649
28 K.Uchida, K.Hayashi,H.Kuramochi, et al. ERCC1 expression as a predictor for chemosensitivity in recurrent colorectal ca- ncer patients receiving cisplatinum (CDDP) plus S-1 chemo-therapy. Journal of Clinical Oncology, 2006 ASCO Annual Meeting proceedings,2006:13065
29 Stephanie Smith, Dan Su, et al.ERCC1 Genotype and Pheno type in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum- Based Therapy. Journal of Clinical Oncology,2007,25(33): 5172~5179
30 Hirotoshi Kobayashi, Kenichi Sugihara, Hiroyuki Uetake, et al.Messenger RNA expression of TS and ERCC1 in primary col orectal cancer and corresponding liver etastasis. Cancer Prevention Research,2006,12~15,B119
31 H-C Kwon, MS Roh, SY Oh, et al.Prognostic value of expre ssion of ERCC1, thymidylate synthase, and glutathione S- transfer rase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Annals of Oncology, 2007,18(3): 504~509
32 Johannes Grillari, Hermann Katinger, Regina Voglauer, et al. Contributions of DNA interstrand crosslinks to aging of cells and organisms. Nucleic Acids Research,2007,35(22):7566~ 7576
33 Yoshino, T.Takenaka, H.Koso, et al.Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer.Journal of Clinical Oncology,2007 ASCO Annual Meeting Proceedings,2007: 18085
34 Stephanie Smith, Dan Su, Irene A. ERCC1 Genotype andPhenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum Based Therapy.Journal of Clinical Oncology, 2007,25(33):5172~5179
1 Tuschl T. RNA interference and Small Interfering RNAs. Chembio,2001,2:239~245
2 陈忠平,Anne MONKS,Timothy G,et al.人肿瘤细胞 ERCC2基因表达与抗癌药耐药的相关性.中山医科大学学报, 2001,22(3):170~173
3 LeMorvan V, Bellott R, Moisan F,et al. Relationships betw- een genetic polymorphisms and anticancer drug cytotoxicityvis-à-vis the NCI-60 panel. Pharmacogenomics.2006,7(6): 843~852
4 Manish A.Shah Gary K. Schwartz.Cell Cycle-mediated Drug Resistance An Emerging Concept in Cancer Therapy. Clinical Cancer Research,2001,7:2168~2181
5 Wang X.W,Vermeulen W, Coursen J.D, et al. The XPB and XPD helicases are components of the p53-mediated apoptosis pathway. Genes Dev,1996,10:1219~1232
6 Wang X.W,YeH,Schaeffer L,et al.p53 modulation of TFIIH- associated nucleotide excision repair activity. Nat. Genet, 1995, 10:188~195
7 Schaeffer L, Roy R, Humbert S, et al. DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor. Science, 1993,260:58~63
8 Weeda G,van Ham C,Vermeulen W, et al. A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne’s syndrome. Cell,1990,62:777~791
9 Mariana Fregoso, Jean-Philippe Lainé, et al.DNA Repair and Transcriptional Deficiencies Caused by Mutations in the Drosophila p52 Subunit of TFIIH Generate Developmental Defects and Chromosome Fragility. Molecular and Cellular Biology, 2007, 27(10):3640~3650
10 Mariana Fregoso, Jean-Philippe Lainé, et al. DNA Repair and Transcriptional Deficiencies Caused by Mutations in the Drosophila p52 Subunit of TFIIH Generate DevelopmentalDefects and Chromosome Fragility. Molecular and Cellular Biology,2007,27(10):3640~3650
11 Narendra Tuteja,Renu Tuteja,et al.Unraveling DNA helicases Motif, structure, mechanism and function. Biochem,2004, 271:1849~1863
12 Christina Justenhoven,Ute Hamann,Beate Pesch,et al.ERCC2 Genotypes and a Corresponding Haplotype Are Linked with Breast Cancer Risk in a German Population. Cancer Epidem -iology Biomarkers & Prevention, 2004,13: 2059~ 2064
13 AzizSancar.Excision Repair in Mammalian Cells.Biochemis try and Molecular Biology,1995,270:15915~15918
14 Carlos Merino,Enrique Reynaud,Martha Vázquez,et al.DNA Repair and Transcriptional Effects of Mutations in TFIIH in Drosophila Development. MBC,2002,13(9):3246~3256
15 Seker H,Butkiewicz D,Bowman ED, et al. Functional signify cance of XPD polymorphic variants:attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res,2001,61:7430~7434
1 Chen Z P,Yarosh D,Garcia Y,et al.Relationship between O6- methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosoureatherapy in glio- ma patients.Can J Neuro Sci,1999,26(2):104
2 刘静,瞿全新,靡若然等.RNA干扰ERCC1基因表达对卵巢癌细胞耐药的影响.河北医学,2006,12:893~895
3 逯晓波,安春丽,孟庆凯等.草酸铂耐药性与 ERCC1 基因表达相关性.中国公共卫生,2006,22:461~462
4 刘国艳,瞿全新,糜若然等.RNA 干扰技术抑制切除修复交叉互补基因 1 对卵巢上皮性癌细胞顺铂敏感性的影响.中华妇产科杂志,2006,41(5):339~342
5 George R. Simon, MD, FCCP, et al. ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer. Chest,2005,127:978~983
6 Rafael Rosell,Vincente Alberola,et al.Ribonucle otide Reduc tase Messenger RNA Expression and Survival in Gemcita- bine/Cisplatin Treated Advanced Non-Small-Cell-Lung-Ca- ner Patients.Clinical Cancer Research,2004,10:1318~1325
7 Rudolf Napieralski, Markus Kremer, et al. ombined GADD- 45A and Thymidine Phosphorylase Expression LevelsPre-dict Response and Survival of Neoadjuvant Treated Gastric-Cancer Patients.Cli Cancer Res,2005,11:3025~3031
8 Mary-Beth Joshi,Yoshinori,Danenberg,et al.High Gene expr ession of TS1, GSTP1, and ERCC1 Are risk factors for sur- vival in patients treated with trimodality therapy for Esopha- geal Cancer. Clinical Cancer Research,2005,11:2215~2221
9 Rupert Langer, Katja Specht, Karen Becker,et al.Association of Pretherapeutic Expression of Chemotherapy-Related Genes with Response to Neoadjuvant Chemotherapy in Barr- ett Carcinoma.Clinical Cancer Res,2005,11:7462~7469
10 P Ceppi,M Volante,S Novello,et al.ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.Oncology,2006,17(12):1818~1825
11 K.Uchida, K.Hayashi, H.Kuramochi,et al.ERCC1 expression as a predictor for chemosensitivity in recurrent colorectal cancer patients receiving cisplatinum (CDDP) plus S-1 chemotherapy. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Pro ceedings
12 Jean-Charles Soria.ERCC1 Tailored Chemotherapy in Lung Cancer:The First Prospective Randomized Trial.Journal of Clin ical Oncology,2007,25:2648~2649
13 J Bellmunt, L Paz-Ares,M Cuello,et al.Gene expression of ERCC1 as a novel prognostic marker in advanced bladder can cer patients receiving cisplatin-based chemotherapy. Annals of Oncology,2007,18(3):522~528
14 Geoffrey Liu, Ariela L. Marshall,et al. Treatment outcomes of advanced esophageal cancer patients and polymorphisms of nucleotide and base excision repair pathway genes. Cancer Res, 2006,47,Abstract #5665
15 Step Smith,Dan Su,Ire A,et al.ERCC1 Genotype and Phen- type in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Pla-Based Therapy.Journal of Cli Oncology,2007,25(33):5172~5179
16 K.Steff, M.Wald,U.Jep,et al.Prediction of response to chemo- therapy by ERCC1 immunohistochemistrtry and ERCC1 po- lymorphism in ovarian cancer. Journal of Clinical Oncology, 2007,ASCO Annual Meeting 2007,25(18):5568
17 E.Felip, R.Rosell, M.Taron, et al. ERCC1, RRM1 and XPD mRNA expression as a predictive marker of outcome in non- small-cell lung cancer patients after platinum/gemcitabine indu ction chemotherapy followed by surgery. Journal of Clinical Oncology,2004 ASCO Annual Meeting,2004:7142
18 Hemminki K, Xu G, Angelini S, et al. XPD exon 10 and 23 polymorphisms and DNA repair in human skin in situ. Carcino genesis,2001;22:1185~1188
19 陈忠平,Cerard Mohr,Lawrence Panasci,et al.胶质瘤细胞ERCC2 表达和氯乙基亚硝脲耐药.中华神经外科杂志, 1999,15(6):365~367
20 陈忠平,Anne Monks,Timothy G.Myres,et al.人肿瘤细胞ERCC2 基因表达与抗癌药耐药的相关性.中山医科大学学报,2001,22(3):170~173
21 Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemothe rapy. Clin Oncol,2004;22:2594~601
22 Daniela F. Giachino, Paolo Ghio, Silvia Regazzoni,et al. Pro spective Assessment of XPD Lys751Gln and XRCC1 Arg- 399-Gln Single Nucleotide Polymorphisms in Lung Cancer. Clinical Cancer Research,2007,13(15):2876~2881
23 J.Wei,B.Liu,Z.Zou,et al.ERCC1 mRNA expression and XR CC1 polymorphism as predictive factors for overall survival in gastric cancer patients receiving platinum based chemo- therapy.Clinical Oncology,2007ASCO Annual Meeting
24 Marintchev A,Robertson A,Dimitriadis EK,et al. Domain Specific interaction in the XRCC1-DNA polymerase beta complex. Nucleic Acids Res,2000,28(10):2049
25 ValentinisB, ZaffaroniN, SturaniE, et al. Deteetion of DNA Polymerase betagene expression by eompetive polymerase- hain Reaetion in human ovarian ea reinomaeells, Antieaneer. 1993,13(1):125~128
26 CanitrotY,CazauxC,FreehetM,et al. Over expression of DNA Polymerase betaineell results in amutat or Phenoty Peanda decreased sensitivity to anti-cancer drugs.ProeNatlAeadSei, 1998,95:12586~12590
27 Corinne Chab,Cami Lamare,Carine,et al.BRCA1 deficiency mediates paclitaxel resistance through premature inactiva-tion of spindle checkpoint in breast cancer cells.Cancer Res, 2006,47:Abstract #3204
28 Egawa C,Motomura K, Miyoshi Y, et al.Increased expre- ssion of BRCA1mRNA predicts favorable response to anthracycl- ine containing chemotherapy in breast cancers. Breast Cancer Res,Treat.2003,78(1):45~50
29 R.Rosell, E. Jassem, M.Skr,et al. Increased BRCA1 mRNA: An independent prognostic variable in completely resected non-small cell lung cancer (NSCLC) patients. Clinical Oncology,2007 ASCO Annual Meeting,2007:7551
30 Miquel Taron, Rafael Rosell, Enriqueta Felip,et al. BRCA1 mRNA expression levels as indicator of chemoresistance in lung cancer.Human Mole Gene,2004,13(20):2443~2449
31 陈芹,周彩存,张颉等. ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义.肿瘤,2007,27(9):719~721
32 Xinjian Lin,Tsuy Oku,Julie Tra,et al.Human REV1 Modu- lates the Cytotoxicity and Mutagenicity of Cisplatin in hu man Ovarian Carcinoma Cells. Molecular Pharmacology, 2006.1,(69):1748~1754
33 Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood,2003,101:822~826
34 D'Andr AD,Grompe M. The Fanconi anaemia/BRCA path way. Nat Rev Cancer,3:23~34
35 Hussain,S,Uit E, Direct interaction of the Fanconi with RCA2/FANCD1.Hum.Mol.Genet,2003,12:2503~2510
36 Tanigu,T,Tischkowitz, M, et al. Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors.Nat.Med, 2003,9:568~574
37 Alis Holzer,Nissi M.Varki,Quynh T.Le,et al. Expression of te Human Copper Influx Transporter 1 in Normal and Malig nant Human Tissues. Journal of Histochemistry and Cytochemi stry,2006,54 (9):1041~1049
1 Rao S, Orr GA, Chaudhary AG,et al. Characterization of the taxol binding site on the microtubule .J Biol Chem, 1995,270 (35):20235~20238
2 Rao S, Kra NE, Heerding JM, et al.3'-(p-Azidoben) taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem,1994,269:3132~3134
3 Mariano Mon, Rafael Rosell, Sánchez.Paclitaxel resistance in Non-Small-Cell Lung Cancer Associated With beta–Tub- ulin Gene Mutations. Clinical Oncology,1999,17, 6):1786
4 Mu JH, Sidhu RS,et al.Analysis of beta-tubulin cDNAs from taxol-resistant pestalotiopsis microspora and taxol- sensitive Pythium ultimum and comparison of the taxol-binding properties of their products.Mol Genet,1999,262:857~868
5 Mariano Monzó,Rafael Rosell,Sánchez,et al. Paclitaxel Re- sistance in Non-Small-Cell Lung Cancer Associated withbeta-tubulin Gene Mutations.Journal of Clinical Oncology, 1999,17,(6):1786
6 Kgu-Ho-Han E,Gehrke L,Tahir SK,et al. Mldulation of drug resistance by α-tublin in paclitaxel-resistant human lung cancer cell lines.Eur J Cancer,2000,36:1565~1571
7 Pascal Sève, Sylvie Isaac,et al. Expression of Class III ?-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving NVB-based Chemo therapy.Clinical Cancer Research,2005,11:5481~5486
8 Kumagai A,Dunphy WG,et al.Purification and molecular cloning of Plx1, a Cdc25 regulatory Kinase from Xenopus egg extracts.Science, 1996,273(6):1377~1380
9 R.Hoover,M.W.Har.Activity of the aurora kinase inhibitor MK-0457in combination with taxotere. Journal of Clinical Oncology, 2007 ASCO Annual Meeting 2007:14069
10 Balázs Sarka,Homolya,et al. Human Multi- drug Resistance ABCB and ABCG Transporters:Participa tion in a Chemoi- mmunity Defense System.Physiol.Rev,2006,86:1179~1236
11 Hori S.Selective gene silencing of rat ATP-binding cassette G2 transporter in an in vitro blood-brain barrier model by short interfering RNA.Neurochem,2005,93:63~71
12 Deeley RG.Transmembrane transport of endo and xeno- biotics by the ATP binding cassette multidrug resistance proteins (MRPs).Physiol Rev,2006,86:849~899
13 Tatsushi Shimokuni, Keiji Tanimoto.Chemosensitivity predi- ction models using expression data of selected marker genes.Clinical Research,2004,45:4741
14 Jurjen S. Lagas, Maria L.Vlaming, Olaf van Tellingen,et al. Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics.Clinical Cancer Research, 2006,12:6125~6132
15 Henrik Gréen, Per Rosenberg. mdr-1 Single Nucleotide Polymorphisms in Ovarian Cancer Tissue:G2677T/A Cor- relates with Response to Paclitaxel Chemotherapy. Clinical Cancer Research,2006,12:854~859
16 Xifeng Wu, Jian Gu, Tsung-Teh Wu, et al. Genetic Variations in Radiation and Chemotherapy Drug Action Pathways Predict Clinical Outcomes in Esophageal Cancer.Journal of Clinical Oncology,2006,24(23):3789~3798
17 Wrighton SA,Brian WR,Sari MA,et al.Studies on the expre- ssion and metabolic capabilities of human liver cytochrome P450IIIA5. Mol. Pharmacol,1990,38:207~213
18 Carolyn D.Britten, Sharyn D.Baker, Louis J. Denis,et al.Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinica- lly Relevant Systemic Exposure to Paclitaxel.Clinical Cancer Research,2000,6:3459~3468
19 Nabeya Y, Maslak P. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int.Cancer, 1999, 464:1~10
20 Cassinelli G,Supino R,Perego P,et al. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.Cancer,2001,92(5):738~747
21 Luo D,Cheng SC, Xie H, et al. Chemosensitivity of human hepa-tocellular carcinoma cell line QGY-7703 is related to bcl-2 proteinlevels. Tumour Biol,1999,20(6):331~340
22 Nabholtz JM,MaekeyJ.Phase 111 trail Paring TAC (doeetaxel,doxorubiein,eyelophosphamide) withFAC (5-fluo rouraeil,doxorubiein,eyelophosphamide) in the adjuvant tr- eatment of node positive breast cancer (BC) patients: Interim Analysis of the BCIRG001 study. Pro emso Clinical, 2002,21:141
23 Zhang L,Lau YK,Xia W,et al. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.Clin Cancer Res,1999,5:343~353
24 Yu D, Liu B, Tan M, et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene,1996,13:1359 ~1365
25 Bali P, Pranpat , Swaby R, et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res.2005,11:6382~6389
26 Slamon DJ, Leyland-Jones B, Shak S,et al. Use of chemo- therapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Engl Med,2001, 344:783~792
27 Timothy Wiltshire,Jamie Senft,Yutian Wang,et al.BRCA1 contributes to cell cycle arrest andchemoresistance in response to the Anticancer Agent Irofulven. Molecular Pharmacology Fast Forward,200717,(71):1051~1060
28 Corinne Chabalier,Carine Racca,et al.BRCA1 deficiency mediates paclitaxel resistance through premature inactiva- tion of spindle checkpoint in breast cancer cells. Proc Amer Assoc Cancer Res,2006,47:3204
29 C.Collins,J.Xu.Relationship between BRCA1 promoter methylation and sensitivity of breast cancer cell lines to cisplatin and paclitaxel. Journal of Clinical Oncology.2007 ASCO Annual Meeting Proceedings,2007:21083
30 Le Morvan V,Bellott R,et al.Relationships between genetic polymorphisms and anticancer drug cytotoxicity visavis the NCI-60 panel.Pharmacogenomics, 2006,7(6):843~852
31 陈忠平,Anne MONKS,Timothy G,et al.人肿瘤细胞 ERCC2基因表达与抗癌药耐药的相关性.中山医科大学学报,2001,22(3):170~173
2 Pierre-Henri L,Gailld and RichardD. Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair. Nucleic Acids Research, 2001, 29(4): 872~879
3 Dabholkar MD, Berger MS, Vionnet JA, et al. Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. CancerRes, 1995, 55:1261~1266
4 Laat W. L, Jaspers G, HoeijmaJ, et al.Molecular mechanicsm of nucleotide excision repair.Genes Dev,1999,13:768~785
5 Chen,JS. Larochelle, X. Li, et al. Xpd/Ercc2 regulates CAK activity and mitotic progression.Nature,2003,4(24):228~232
6 Egly, J. M. TFIIH: from transcription to clinic. FEBS Lett, 2001,498:124~128
7 Fisher, R. P. Secrets of a double agent: CDK7 in cell cycle control and transcription. Cell Sci, 2005,118:5171~5180
8 Morgan, D. O, et al.Principles of CDK regulation. Nature, 1995,374:131~134
9 陈忠平,Anne MONKS,Timoth G,et al.人肿瘤细胞 ERCC2基因表达与抗癌药耐药的相关性.中山医科大学学报, 2001,22(3):170~173
10 Dabholkar M,Bostick-Bruton F,Weber C,et al.Expression ofexcision repair genes in non-malignant bone marrow from cancer patients.Res,1993,293(2):151~160
11 G Weeda, I. Donker, J de Wit, et al. Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence.Cur Biol,1997, 7:427~439
12 黄培钰 , 梁晓曼 , 张力等 . 晚期非小细胞肺癌组织中ERCC1、Metallothionein、p53 表达与铂类耐药性及预后的相关性分析.癌症,2004,23(7):845~850
13 Gerard Mohr, Lawrence C Panasci, 陈忠平等. PCR 定量分析 ERCC2 基因在人类肿瘤细胞中的表达.江苏医药,1998,24(11):781~784
14 汤春辉,顾星星.卵巢癌实体瘤 ERCC2 表达与肿瘤发生及耐药的关系.肿瘤研究与临床,2004,16(1):14~16
15 周宜开,吕斌,张霞等.DNA 切除修复标志物在肺癌、食管癌组织中的表达.环境与职业医学,2003,20(3):145~147
16 Rafael Rosell, Enriqueta Felip, Miquel Taron, et al. Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery. Clinical Cancer Research,2004,10:4215~4219
17 SelvakumaranM, Pisarcik DA, Bao R, et al.Enhanced cis- platin cytotoxicity by disturbing the nucleotide excision repair path way in ovarian cancer cell lines CancerRes,2003, 63:1311~1316
18 Lee KB, Parker RJ, Reed E. Cisplatin sensitivity/resistance in UV repair deficient Chinese hamster ovary cells of complement ation groups 1 and 3.Carcinogenesis, 1993,14: 77~80
19 Yu JJ, Mu C, Reed E, et al.Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. Int J Mol Med,1998,1:17~20
20 Yu JJ, Thornton K, Reed E, et al. An ERCC1 splicing variant involving the 5'UTR of the mRNA may have a transcription- al modulatory function. Oncogene, 2001, 20:7694
21 Dabholkar M, Vionnet J,Bostick-Bruton FE, et al. Expression of an alternatively spliced ERCC1 mRNA species is relatedto reduced DNA repair efficiency in human T lymphocytes. Oncology Rep,1995,2:9~14.
22 Eddie Reed. ERCC1 and Clinical Resistance to Platinum Based Therapy. Clinical Cancer Research, 2005,11:6100~ 6102
23 R. Rosell, M. Cobo, D. Isla, et al.Pharmacogenomics and gemcitabine. Annals of Oncology,2006,17:13~16
24 Eddie Reed.ERCC1 and Clinical Resistance to Platinum Based Therapy.Clinical Cancer Research,2005,11:6100~ 6102
25 P Ceppi, M Volante, S Novello, et al. ERCC1 and RRM1 gene e expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Annals of Oncology, 2006, 17(12): 1818~1825
26 K. Lee, S. Han, H. Min, et al. ERCC1 expression by immuno histochemistry and EGFR mutations in resected non-small cell lung cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings,2007:7646
27 Jean-Charles Soria.ERCC1-Tailored Chemotherapy in Lung Cancer: The First Prospective Randomized Trial.Journal of Clinical Oncology,2007,25, (19 ):2648~2649
28 K.Uchida, K.Hayashi,H.Kuramochi, et al. ERCC1 expression as a predictor for chemosensitivity in recurrent colorectal ca- ncer patients receiving cisplatinum (CDDP) plus S-1 chemo-therapy. Journal of Clinical Oncology, 2006 ASCO Annual Meeting proceedings,2006:13065
29 Stephanie Smith, Dan Su, et al.ERCC1 Genotype and Pheno type in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum- Based Therapy. Journal of Clinical Oncology,2007,25(33): 5172~5179
30 Hirotoshi Kobayashi, Kenichi Sugihara, Hiroyuki Uetake, et al.Messenger RNA expression of TS and ERCC1 in primary col orectal cancer and corresponding liver etastasis. Cancer Prevention Research,2006,12~15,B119
31 H-C Kwon, MS Roh, SY Oh, et al.Prognostic value of expre ssion of ERCC1, thymidylate synthase, and glutathione S- transfer rase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Annals of Oncology, 2007,18(3): 504~509
32 Johannes Grillari, Hermann Katinger, Regina Voglauer, et al. Contributions of DNA interstrand crosslinks to aging of cells and organisms. Nucleic Acids Research,2007,35(22):7566~ 7576
33 Yoshino, T.Takenaka, H.Koso, et al.Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer.Journal of Clinical Oncology,2007 ASCO Annual Meeting Proceedings,2007: 18085
34 Stephanie Smith, Dan Su, Irene A. ERCC1 Genotype andPhenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum Based Therapy.Journal of Clinical Oncology, 2007,25(33):5172~5179
1 Tuschl T. RNA interference and Small Interfering RNAs. Chembio,2001,2:239~245
2 陈忠平,Anne MONKS,Timothy G,et al.人肿瘤细胞 ERCC2基因表达与抗癌药耐药的相关性.中山医科大学学报, 2001,22(3):170~173
3 LeMorvan V, Bellott R, Moisan F,et al. Relationships betw- een genetic polymorphisms and anticancer drug cytotoxicityvis-à-vis the NCI-60 panel. Pharmacogenomics.2006,7(6): 843~852
4 Manish A.Shah Gary K. Schwartz.Cell Cycle-mediated Drug Resistance An Emerging Concept in Cancer Therapy. Clinical Cancer Research,2001,7:2168~2181
5 Wang X.W,Vermeulen W, Coursen J.D, et al. The XPB and XPD helicases are components of the p53-mediated apoptosis pathway. Genes Dev,1996,10:1219~1232
6 Wang X.W,YeH,Schaeffer L,et al.p53 modulation of TFIIH- associated nucleotide excision repair activity. Nat. Genet, 1995, 10:188~195
7 Schaeffer L, Roy R, Humbert S, et al. DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor. Science, 1993,260:58~63
8 Weeda G,van Ham C,Vermeulen W, et al. A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne’s syndrome. Cell,1990,62:777~791
9 Mariana Fregoso, Jean-Philippe Lainé, et al.DNA Repair and Transcriptional Deficiencies Caused by Mutations in the Drosophila p52 Subunit of TFIIH Generate Developmental Defects and Chromosome Fragility. Molecular and Cellular Biology, 2007, 27(10):3640~3650
10 Mariana Fregoso, Jean-Philippe Lainé, et al. DNA Repair and Transcriptional Deficiencies Caused by Mutations in the Drosophila p52 Subunit of TFIIH Generate DevelopmentalDefects and Chromosome Fragility. Molecular and Cellular Biology,2007,27(10):3640~3650
11 Narendra Tuteja,Renu Tuteja,et al.Unraveling DNA helicases Motif, structure, mechanism and function. Biochem,2004, 271:1849~1863
12 Christina Justenhoven,Ute Hamann,Beate Pesch,et al.ERCC2 Genotypes and a Corresponding Haplotype Are Linked with Breast Cancer Risk in a German Population. Cancer Epidem -iology Biomarkers & Prevention, 2004,13: 2059~ 2064
13 AzizSancar.Excision Repair in Mammalian Cells.Biochemis try and Molecular Biology,1995,270:15915~15918
14 Carlos Merino,Enrique Reynaud,Martha Vázquez,et al.DNA Repair and Transcriptional Effects of Mutations in TFIIH in Drosophila Development. MBC,2002,13(9):3246~3256
15 Seker H,Butkiewicz D,Bowman ED, et al. Functional signify cance of XPD polymorphic variants:attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res,2001,61:7430~7434
1 Chen Z P,Yarosh D,Garcia Y,et al.Relationship between O6- methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosoureatherapy in glio- ma patients.Can J Neuro Sci,1999,26(2):104
2 刘静,瞿全新,靡若然等.RNA干扰ERCC1基因表达对卵巢癌细胞耐药的影响.河北医学,2006,12:893~895
3 逯晓波,安春丽,孟庆凯等.草酸铂耐药性与 ERCC1 基因表达相关性.中国公共卫生,2006,22:461~462
4 刘国艳,瞿全新,糜若然等.RNA 干扰技术抑制切除修复交叉互补基因 1 对卵巢上皮性癌细胞顺铂敏感性的影响.中华妇产科杂志,2006,41(5):339~342
5 George R. Simon, MD, FCCP, et al. ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer. Chest,2005,127:978~983
6 Rafael Rosell,Vincente Alberola,et al.Ribonucle otide Reduc tase Messenger RNA Expression and Survival in Gemcita- bine/Cisplatin Treated Advanced Non-Small-Cell-Lung-Ca- ner Patients.Clinical Cancer Research,2004,10:1318~1325
7 Rudolf Napieralski, Markus Kremer, et al. ombined GADD- 45A and Thymidine Phosphorylase Expression LevelsPre-dict Response and Survival of Neoadjuvant Treated Gastric-Cancer Patients.Cli Cancer Res,2005,11:3025~3031
8 Mary-Beth Joshi,Yoshinori,Danenberg,et al.High Gene expr ession of TS1, GSTP1, and ERCC1 Are risk factors for sur- vival in patients treated with trimodality therapy for Esopha- geal Cancer. Clinical Cancer Research,2005,11:2215~2221
9 Rupert Langer, Katja Specht, Karen Becker,et al.Association of Pretherapeutic Expression of Chemotherapy-Related Genes with Response to Neoadjuvant Chemotherapy in Barr- ett Carcinoma.Clinical Cancer Res,2005,11:7462~7469
10 P Ceppi,M Volante,S Novello,et al.ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.Oncology,2006,17(12):1818~1825
11 K.Uchida, K.Hayashi, H.Kuramochi,et al.ERCC1 expression as a predictor for chemosensitivity in recurrent colorectal cancer patients receiving cisplatinum (CDDP) plus S-1 chemotherapy. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Pro ceedings
12 Jean-Charles Soria.ERCC1 Tailored Chemotherapy in Lung Cancer:The First Prospective Randomized Trial.Journal of Clin ical Oncology,2007,25:2648~2649
13 J Bellmunt, L Paz-Ares,M Cuello,et al.Gene expression of ERCC1 as a novel prognostic marker in advanced bladder can cer patients receiving cisplatin-based chemotherapy. Annals of Oncology,2007,18(3):522~528
14 Geoffrey Liu, Ariela L. Marshall,et al. Treatment outcomes of advanced esophageal cancer patients and polymorphisms of nucleotide and base excision repair pathway genes. Cancer Res, 2006,47,Abstract #5665
15 Step Smith,Dan Su,Ire A,et al.ERCC1 Genotype and Phen- type in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Pla-Based Therapy.Journal of Cli Oncology,2007,25(33):5172~5179
16 K.Steff, M.Wald,U.Jep,et al.Prediction of response to chemo- therapy by ERCC1 immunohistochemistrtry and ERCC1 po- lymorphism in ovarian cancer. Journal of Clinical Oncology, 2007,ASCO Annual Meeting 2007,25(18):5568
17 E.Felip, R.Rosell, M.Taron, et al. ERCC1, RRM1 and XPD mRNA expression as a predictive marker of outcome in non- small-cell lung cancer patients after platinum/gemcitabine indu ction chemotherapy followed by surgery. Journal of Clinical Oncology,2004 ASCO Annual Meeting,2004:7142
18 Hemminki K, Xu G, Angelini S, et al. XPD exon 10 and 23 polymorphisms and DNA repair in human skin in situ. Carcino genesis,2001;22:1185~1188
19 陈忠平,Cerard Mohr,Lawrence Panasci,et al.胶质瘤细胞ERCC2 表达和氯乙基亚硝脲耐药.中华神经外科杂志, 1999,15(6):365~367
20 陈忠平,Anne Monks,Timothy G.Myres,et al.人肿瘤细胞ERCC2 基因表达与抗癌药耐药的相关性.中山医科大学学报,2001,22(3):170~173
21 Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemothe rapy. Clin Oncol,2004;22:2594~601
22 Daniela F. Giachino, Paolo Ghio, Silvia Regazzoni,et al. Pro spective Assessment of XPD Lys751Gln and XRCC1 Arg- 399-Gln Single Nucleotide Polymorphisms in Lung Cancer. Clinical Cancer Research,2007,13(15):2876~2881
23 J.Wei,B.Liu,Z.Zou,et al.ERCC1 mRNA expression and XR CC1 polymorphism as predictive factors for overall survival in gastric cancer patients receiving platinum based chemo- therapy.Clinical Oncology,2007ASCO Annual Meeting
24 Marintchev A,Robertson A,Dimitriadis EK,et al. Domain Specific interaction in the XRCC1-DNA polymerase beta complex. Nucleic Acids Res,2000,28(10):2049
25 ValentinisB, ZaffaroniN, SturaniE, et al. Deteetion of DNA Polymerase betagene expression by eompetive polymerase- hain Reaetion in human ovarian ea reinomaeells, Antieaneer. 1993,13(1):125~128
26 CanitrotY,CazauxC,FreehetM,et al. Over expression of DNA Polymerase betaineell results in amutat or Phenoty Peanda decreased sensitivity to anti-cancer drugs.ProeNatlAeadSei, 1998,95:12586~12590
27 Corinne Chab,Cami Lamare,Carine,et al.BRCA1 deficiency mediates paclitaxel resistance through premature inactiva-tion of spindle checkpoint in breast cancer cells.Cancer Res, 2006,47:Abstract #3204
28 Egawa C,Motomura K, Miyoshi Y, et al.Increased expre- ssion of BRCA1mRNA predicts favorable response to anthracycl- ine containing chemotherapy in breast cancers. Breast Cancer Res,Treat.2003,78(1):45~50
29 R.Rosell, E. Jassem, M.Skr,et al. Increased BRCA1 mRNA: An independent prognostic variable in completely resected non-small cell lung cancer (NSCLC) patients. Clinical Oncology,2007 ASCO Annual Meeting,2007:7551
30 Miquel Taron, Rafael Rosell, Enriqueta Felip,et al. BRCA1 mRNA expression levels as indicator of chemoresistance in lung cancer.Human Mole Gene,2004,13(20):2443~2449
31 陈芹,周彩存,张颉等. ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义.肿瘤,2007,27(9):719~721
32 Xinjian Lin,Tsuy Oku,Julie Tra,et al.Human REV1 Modu- lates the Cytotoxicity and Mutagenicity of Cisplatin in hu man Ovarian Carcinoma Cells. Molecular Pharmacology, 2006.1,(69):1748~1754
33 Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood,2003,101:822~826
34 D'Andr AD,Grompe M. The Fanconi anaemia/BRCA path way. Nat Rev Cancer,3:23~34
35 Hussain,S,Uit E, Direct interaction of the Fanconi with RCA2/FANCD1.Hum.Mol.Genet,2003,12:2503~2510
36 Tanigu,T,Tischkowitz, M, et al. Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors.Nat.Med, 2003,9:568~574
37 Alis Holzer,Nissi M.Varki,Quynh T.Le,et al. Expression of te Human Copper Influx Transporter 1 in Normal and Malig nant Human Tissues. Journal of Histochemistry and Cytochemi stry,2006,54 (9):1041~1049
1 Rao S, Orr GA, Chaudhary AG,et al. Characterization of the taxol binding site on the microtubule .J Biol Chem, 1995,270 (35):20235~20238
2 Rao S, Kra NE, Heerding JM, et al.3'-(p-Azidoben) taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem,1994,269:3132~3134
3 Mariano Mon, Rafael Rosell, Sánchez.Paclitaxel resistance in Non-Small-Cell Lung Cancer Associated With beta–Tub- ulin Gene Mutations. Clinical Oncology,1999,17, 6):1786
4 Mu JH, Sidhu RS,et al.Analysis of beta-tubulin cDNAs from taxol-resistant pestalotiopsis microspora and taxol- sensitive Pythium ultimum and comparison of the taxol-binding properties of their products.Mol Genet,1999,262:857~868
5 Mariano Monzó,Rafael Rosell,Sánchez,et al. Paclitaxel Re- sistance in Non-Small-Cell Lung Cancer Associated withbeta-tubulin Gene Mutations.Journal of Clinical Oncology, 1999,17,(6):1786
6 Kgu-Ho-Han E,Gehrke L,Tahir SK,et al. Mldulation of drug resistance by α-tublin in paclitaxel-resistant human lung cancer cell lines.Eur J Cancer,2000,36:1565~1571
7 Pascal Sève, Sylvie Isaac,et al. Expression of Class III ?-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving NVB-based Chemo therapy.Clinical Cancer Research,2005,11:5481~5486
8 Kumagai A,Dunphy WG,et al.Purification and molecular cloning of Plx1, a Cdc25 regulatory Kinase from Xenopus egg extracts.Science, 1996,273(6):1377~1380
9 R.Hoover,M.W.Har.Activity of the aurora kinase inhibitor MK-0457in combination with taxotere. Journal of Clinical Oncology, 2007 ASCO Annual Meeting 2007:14069
10 Balázs Sarka,Homolya,et al. Human Multi- drug Resistance ABCB and ABCG Transporters:Participa tion in a Chemoi- mmunity Defense System.Physiol.Rev,2006,86:1179~1236
11 Hori S.Selective gene silencing of rat ATP-binding cassette G2 transporter in an in vitro blood-brain barrier model by short interfering RNA.Neurochem,2005,93:63~71
12 Deeley RG.Transmembrane transport of endo and xeno- biotics by the ATP binding cassette multidrug resistance proteins (MRPs).Physiol Rev,2006,86:849~899
13 Tatsushi Shimokuni, Keiji Tanimoto.Chemosensitivity predi- ction models using expression data of selected marker genes.Clinical Research,2004,45:4741
14 Jurjen S. Lagas, Maria L.Vlaming, Olaf van Tellingen,et al. Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics.Clinical Cancer Research, 2006,12:6125~6132
15 Henrik Gréen, Per Rosenberg. mdr-1 Single Nucleotide Polymorphisms in Ovarian Cancer Tissue:G2677T/A Cor- relates with Response to Paclitaxel Chemotherapy. Clinical Cancer Research,2006,12:854~859
16 Xifeng Wu, Jian Gu, Tsung-Teh Wu, et al. Genetic Variations in Radiation and Chemotherapy Drug Action Pathways Predict Clinical Outcomes in Esophageal Cancer.Journal of Clinical Oncology,2006,24(23):3789~3798
17 Wrighton SA,Brian WR,Sari MA,et al.Studies on the expre- ssion and metabolic capabilities of human liver cytochrome P450IIIA5. Mol. Pharmacol,1990,38:207~213
18 Carolyn D.Britten, Sharyn D.Baker, Louis J. Denis,et al.Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinica- lly Relevant Systemic Exposure to Paclitaxel.Clinical Cancer Research,2000,6:3459~3468
19 Nabeya Y, Maslak P. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int.Cancer, 1999, 464:1~10
20 Cassinelli G,Supino R,Perego P,et al. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.Cancer,2001,92(5):738~747
21 Luo D,Cheng SC, Xie H, et al. Chemosensitivity of human hepa-tocellular carcinoma cell line QGY-7703 is related to bcl-2 proteinlevels. Tumour Biol,1999,20(6):331~340
22 Nabholtz JM,MaekeyJ.Phase 111 trail Paring TAC (doeetaxel,doxorubiein,eyelophosphamide) withFAC (5-fluo rouraeil,doxorubiein,eyelophosphamide) in the adjuvant tr- eatment of node positive breast cancer (BC) patients: Interim Analysis of the BCIRG001 study. Pro emso Clinical, 2002,21:141
23 Zhang L,Lau YK,Xia W,et al. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.Clin Cancer Res,1999,5:343~353
24 Yu D, Liu B, Tan M, et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene,1996,13:1359 ~1365
25 Bali P, Pranpat , Swaby R, et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res.2005,11:6382~6389
26 Slamon DJ, Leyland-Jones B, Shak S,et al. Use of chemo- therapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Engl Med,2001, 344:783~792
27 Timothy Wiltshire,Jamie Senft,Yutian Wang,et al.BRCA1 contributes to cell cycle arrest andchemoresistance in response to the Anticancer Agent Irofulven. Molecular Pharmacology Fast Forward,200717,(71):1051~1060
28 Corinne Chabalier,Carine Racca,et al.BRCA1 deficiency mediates paclitaxel resistance through premature inactiva- tion of spindle checkpoint in breast cancer cells. Proc Amer Assoc Cancer Res,2006,47:3204
29 C.Collins,J.Xu.Relationship between BRCA1 promoter methylation and sensitivity of breast cancer cell lines to cisplatin and paclitaxel. Journal of Clinical Oncology.2007 ASCO Annual Meeting Proceedings,2007:21083
30 Le Morvan V,Bellott R,et al.Relationships between genetic polymorphisms and anticancer drug cytotoxicity visavis the NCI-60 panel.Pharmacogenomics, 2006,7(6):843~852
31 陈忠平,Anne MONKS,Timothy G,et al.人肿瘤细胞 ERCC2基因表达与抗癌药耐药的相关性.中山医科大学学报,2001,22(3):170~173